Exhibit 99.1

Celgene Contacts:
Robert J. Hugin                                              Brian P. Gill
Senior VP and CFO                                            Director PR/IR
Celgene Corporation                                          Celgene Corporation
(908) 673-9102                                               (908) 673-9530


CELGENE LICENSES RIGHTS TO ENTREMED FOR TUBULIN INHIBITOR PROGRAM

SUMMIT, NJ - (MARCH 24, 2005) - CELGENE CORPORATION (NASDAQ: CELG) announced
that it has signed a licensing agreement with EntreMed Corporation (ENMD)
whereby EntreMed has been granted rights to the development and
commercialization of Celgene's tubulin inhibitor compounds, a class of orally
available, anti-proliferative compounds that have demonstrated, in preclinical
models, activity against drug-resistant cancer cells, inhibition of inflammatory
cytokines and anti-angiogenic activity.

"This is another example where Celgene continues to collaborate with industry
partners to optimize the potential of our numerous assets," explained Sol Barer,
President and Chief Operating Officer of Celgene. "We believe that this is a
good partnership for Celgene, and one that fits closely with both Celgene's and
EntreMed's focus to develop a new class of anti-cancer compounds with multiple
mechanisms of action, such as stopping cancer cells from growing by impeding
cell division via tubulin inhibition. In addition, our companies have
complementary skills, so we will look for additional ways to work together in
the future."

Under the terms of the agreement, Celgene will receive an up-front license fee
payment and additional payments upon successful completion of certain clinical,
regulatory and sales milestones. Entremed will provide all resources needed to
conduct clinical research and regulatory activities associated with seeking
marketing approvals of the tubulin inhibitors for oncology applications.

James S. Burns, President and Chief Executive Officer of EntreMed commented,
"This agreement represents an important step forward in our growth plan.
Celgene's dual-acting tubulin inhibitors strengthen our preclinical oncology
pipeline with compounds that attack tumor cells directly and the blood vessels
that nourish them. Our lead product candidate, Panzem(R) NCD, works as both a
microtubule destabilizing agent and as an antiangiogenic agent. We intend to
maintain this focus on multi-mechanism drugs for the treatment of cancer and
inflammatory diseases."

ABOUT TUBULIN INHIBITORS
Celgene's class of tubulin inhibitors are orally available, anti-proliferative
compounds that contain multiple drug candidates and have numerous potential
anti-cancer mechanisms. Tubulins are the proteins that form microtubules, which
are key components of the cellular cytoskeleton (structural network).
Microtubules are necessary for cell division (mitosis), cell structure,
transport, signaling and motility. Given their primary role in mitosis,
microtubules



have been an important target for anticancer drugs -- often referred to as
antimitotic drugs, tubulin inhibitors and microtubule targeting agents. These
compounds bind to tubulin in microtubules and prevent cancer cell proliferation
by interfering with the microtubule formation required for cell division. This
interference blocks the cell cycle sequence, leading to apoptosis. In
preclinical models, Celgene's proprietary tubulin inhibitors have demonstrated
activity against drug-resistant cancer cells, inhibition of inflammatory
cytokines and anti-angiogenic activity.

ABOUT ENTREMED
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic
candidates primarily for the treatment of cancer and inflammation. Panzem(R)
(2-Methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in
clinical trials for cancer, as well as in preclinical development for
indications outside of oncology. EntreMed's goal is to develop and commercialize
new compounds based on the Company's expertise in angiogenesis, cell cycle
regulation and inflammation -- processes vital to the treatment of cancer and
other diseases. Additional information about EntreMed is available on the
Company's website at www.entremed.com and in various filings with the Securities
and Exchange Commission.

ABOUT CELGENE
Celgene Corporation (Nasdaq: CELG), headquartered in Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the discovery,
development and commercialization of innovative therapies for the treatment of
cancer and inflammatory diseases through gene and protein regulation. For more
information, please visit the Company's website at www.celgene.com.

THIS RELEASE CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WHICH INVOLVE KNOWN AND
UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE CONTROL OF
CELGENE OR PHARMION WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS
OF THE CELGENE AND PHARMION TO BE MATERIALLY DIFFERENT FROM THE RESULTS,
PERFORMANCE OR OTHER EXPECTATIONS IMPLIED BY THESE FORWARD-LOOKING STATEMENTS.
THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT
ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND THOSE
FACTORS DETAILED IN THE FILINGS MADE BY CELGENE AND PHARMION WITH THE SECURITIES
AND EXCHANGE COMMISSION SUCH AS 10K, 10Q AND 8K REPORTS. FORWARD-LOOKING
STATEMENTS SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE, AND NEITHER CELGENE
NOR PHARMION UNDERTAKE ANY OBLIGATION TO UPDATE PUBLICLY OR REVISE ANY
FORWARD-LOOKING STATEMENT, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE
DEVELOPMENTS OR OTHERWISE.


                                      # # #